Access to Insulin Commitment

The majority of people with diabetes live in low- and middle-income countries.1 Access to reliable and affordable supplies of insulin is a challenge for many. In fact, it is estimated that 50 million people lack access to insulin worldwide.2

Novo Nordisk has addressed this challenge since we introduced our Differential Pricing Policy for Least Developed Countries (LDCs) in 2001. Our continued commitment to having a low-cost insulin in our product portfolio and to producing and making human insulin available for years to come, is formulated in our Access to Insulin Commitment. With the expanded scope in 2019, the Access to Insulin Commitment today covers a total of 78 countries, home to a third of the world’s diabetes population1, as well as selected humanitarian organisations. 

The commitment builds on the following principles:

  • It is our ambition to continue to be the leading supplier of low-priced human insulin in the world. We wish to provide affordable insulin treatment to significantly more patients in low- and middle-income countries and we are committed to passing on possible future gains in production efficiency to patients.
  • We guarantee that we will provide low-priced human insulin to ensure access to quality treatments for patients in the poorest parts of the world for many years to come. Our guarantee applies to Least Developed Countries (LDCs) as defined by the UNother low-income countries as defined by the World Bank and middle-income countries where large low-income populations lack sufficient health coverage. For the selected humanitarian organisations, the commitment is global in scope.
  • Our guarantee entails that we will provide the human insulin needed at a guaranteed ceiling price. The annual ceiling price will be decided by our Executive Management. The ceiling price for 2019 is set at 4.00 US dollars/vial. The ceiling price applies unless the price is determined by local agreements. The product supplied under this guarantee will be human insulin in vials.

Reach

In 2018, the average selling price was USD 2.89 per vial. As a result, an estimated 0.3 million people were treated with insulin for on average 12 cents per day.3 Beyond this commitment, Novo Nordisk sold human insulin at or below the ceiling price in other countries, reaching an estimated 5 million people in 2018. 

 

References

1. International Diabetes Federation. IDF Diabetes Atlas, 8th edition, 2017

2. ACCISS.  Fact Sheet on Inequities and Inefficiencies in the global insulin market. Amsterdam: Health Action International; 2015. Retrieved from: http://haiweb.org/wp-content/uploads/2015/11/ACCISS-Fact-Sheet-1-Inequalities-in-Insulin-Market.pdf.Accessed September 2016

3. Assuming average daily dose of 40 IU, as per WHO, Drug and Therapeutic Committee - A Practical Guide, 2003, Annex 6.1.


Learn more

Countries where the commitment applies

Position on access to diabetes care

Access to Insulin Commitment Fact Card